Piper Jaffray Downgrades Spring Bank Pharmaceuticals (SBPH) to Neutral
Tweet
Share
E-mailGet Alerts SBPH Hot Sheet
Price: $1.21 --0%
Rating Summary:
3 Buy, 3 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
3 Buy, 3 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Piper Jaffray analyst Edward Tenthoff downgraded Spring Bank Pharmaceuticals (NASDAQ: SBPH) from Overweight to Neutral with a price target of $1.70 (from $10.00).
For an analyst ratings summary and ratings history on Spring Bank Pharmaceuticals click here. For more ratings news on Spring Bank Pharmaceuticals click here.
Shares of Spring Bank Pharmaceuticals closed at $3.61 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Fiserv (FISV) PT Lowered to $60 at Freedom Broker
- UBS Reiterates Buy Rating on NVIDIA (NVDA), Expects Q2 Revenue Beat
- Wolverine World Wide (WWW) PT Raised to $31 at UBS on Growth, EPS Upside Potential
Create E-mail Alert Related Categories
Analyst Comments, DowngradesRelated Entities
Piper Jaffray, Edward TenthoffSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
